Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients

    September 2020 in “ Journal of the European Academy of Dermatology and Venereology ”
    J. Philip McCoy, Carlos Gustavo Wambier, Sabina Herrera, Sergio Vañó‐Galván, Francesca Gioia, Belén Comeche, Raquel Ron, Sergio Serrano‐Villar, Rafal M. Iwasiow, Michael A Tayeb, Flavio Cadegiani, Natasha Atanaskova Mesinkovska, Jerry Shapiro, Rodney Sinclair, Andy Goren
    Image of study
    TLDR A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
    In a prospective longitudinal study of 65 hospitalized COVID-19 male patients, researchers found that a genetic variant in the androgen receptor (AR) gene, specifically the length of the polyglutamine (CAG) repeat, was associated with disease severity. Patients with a longer CAG repeat (CAG>=22) had a higher risk of being admitted to the intensive care unit (ICU) and longer hospital stays compared to those with a shorter CAG repeat (CAG<22). The study excluded subjects taking androgen modifying drugs and used PCR-amplified sequencing to determine CAG repeat length. Among the 34 subjects with a CAG>=22, 24 (70.6%) were admitted to the ICU with a median hospitalization duration of 47.5 days, while among the 31 subjects with a CAG<22, 14 (45.2%) were admitted to the ICU with a median hospitalization duration of 25 days. The findings suggest that AR CAG repeat length could serve as a biomarker for predicting ICU admission risk in male COVID-19 patients, supporting the role of androgens in disease severity. The authors acknowledge the study's small size and encourage further research into anti-androgen treatments for COVID-19.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 1000+ results

      community Binding affinity of pyrilutamide!

      in Update  167 upvotes 2 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community Hair loss causes are still a myth.

      in Chat  16 upvotes 3 years ago
      The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  122 upvotes 1 year ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 4 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

    Similar Research

    5 / 1000+ results